PrecisemAb Biotech Co., Ltd. extends its sincere congratulations to the team at GlycoNex Inc.! We are honored to have collaborated on the development of GNX201, a pro-antibody engineered with our patented AntibodyLock technology that enables selective activation within the tumor microenvironment. The research findings have been published in the international journal International Journal of Biological Macromolecules (Impact Factor: 7.7, ).
The publication details how GNX201 leverages the AntibodyLock mechanism to remain masked in systemic circulation and become fully activated only when cleaved by specific proteases within the tumor region. This design significantly reduces systemic toxicity while preserving therapeutic efficacy, demonstrating the strong potential of our platform in tumor selectivity and future clinical applications.
PrecisemAb Biotech will continue advancing this innovative platform globally, striving to deliver safer and more effective next-generation antibody therapeutics.
Related news:
